Loading clinical trials...
Loading clinical trials...
An Open-label, Randomised, 3-way Crossover Single Dose Study to Demonstrate Dose Proportionality of Fluticasone Furoate (FF) and Equivalence of Vilanterol (VI) When Administered as FF/VI Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects.
Conditions
Interventions
Fluticasone furoate 50 mcg (4 inhalations)
Fluticasone furoate 100 mcg (4 inhalations)
+2 more
Locations
1
United Kingdom
GSK Investigational Site
London, United Kingdom
Start Date
October 4, 2010
Primary Completion Date
November 25, 2010
Completion Date
November 25, 2010
Last Updated
June 14, 2017
NCT07219173
NCT07486401
NCT02327897
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions